Remission in depression: Definition and initial treatment approaches

Journal of Psychopharmacology

Volumn 20, Issue 3 SUPPL., 2006, Pages 5-10

  Israel, Joshua A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antidepressant therapy; Depression; Diagnosis; Monoamine oxidase inhibitors (MAOIs); Remission; Selective serotonin reuptake inhibitors (SSRIs); Tricyclic antidepressants (TCAs)

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; FLUOXETINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGE; AGITATION; CARDIOVASCULAR DISEASE; DEPRESSION; DIARRHEA; DRUG EFFICACY; EVALUATION; EVIDENCE BASED MEDICINE; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; INSOMNIA; NAUSEA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSOCIAL ENVIRONMENT; RATING SCALE; REMISSION; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME; WEIGHT GAIN; WITHDRAWAL SYNDROME;

ANTIDEPRESSIVE AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; HUMANS; PATIENT COMPLIANCE; PATIENT SELECTION; PSYCHOTHERAPY; QUALITY OF LIFE; RECURRENCE; REMISSION INDUCTION; TERMINOLOGY; TERMINOLOGY AS TOPIC; TREATMENT OUTCOME;

EID: 33747153788     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/1359786806064306     Document Type: Review

References (25)

1. Baer L, Jacobs D G, Meszler-Reizes J, Blais M, Fava M, Kessler R, Magruder K, Murphy J, Kopans B, Cukor P, Leahy L, O'Laughlen J (2000) Development of a brief screening instrument: the HANDS. Psychother Psychosom 69: 35-41
2. Drevets W C (2000) Neuroimaging studies of mood disorders. Biol Psychiatry 48: 813-829
3. Fava M, Davidson K G (1996) Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19: 179-200
4. Frank E, Prien R F, Jarrett R B, Keller M B, Kupfer D J, Lavori P W, Rush A J, Weissman M M (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48: 851-855
5. Hirschfeld R M (1999) Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry 60: 326-335
6. Hirschfeld R M, Dunner D L, Keitner G, Klein D N, Koran L M, Kornstein S G, Markowitz J C, Miller I, Nemeroff C B, Ninan P T, Rush A J, Schatzberg A F, Thase M E, Trivedi M H, Borian F E, Crits-Christoph P, Keller M B (2002) Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry 51: 123-133
7. Joyce P R, Mulder R T, Luty S E, McKenzie J M, Rae A M (2003) A differential response to nortriptyline and fluoxetine in melancholic depression: the importance of age and gender. Acta Psychiatr Scand 108: 20-23
8. Keller M B (2003) Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 289: 3152-3160
9. Lecrubier Y (2002) How do you define remission? Acta Psychiatr Scand Suppl 106 (suppl 415): 7-11
10. McGrath P J, Stewart J W, Janal M N, Petkova E, Quitkin F M, Klein D F (2000) A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry 157: 344-350
11. Matza L S, Revicki D A, Davidson J R, Stewart J W (2003) Depression with atypical features in the National Comorbidity Survey: classification, description, and consequences. Arch Gen Psychiatry 60: 817-826
12. Melartin T K, Rytsala H J, Leskela U S, Lestela-Mielonen P S, Sokero T P, Isometsa E T (2004) Severity and comorbidity predict episode duration and recurrence of DSM-IV major depressive disorder. J Clin Psychiatry 65: 810-819
13. Nierenberg A A, Keefe B R, Leslie V C, Alpert J E, Pava J A, Worthington J J, III, Rosenbaum J F, Fava M (1999) Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 60: 221-225
14. Parker G (2002) Differential effectiveness of newer and older antidepressants appears mediated by an age effect on the phenotypic expression of depression. Acta Psychiatr Scand 106: 168-170
15. Paykel E S, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A (1995) Residual symptoms after partial remission: an important outcome in depression. Psychol Med 25: 1171-1180
16. Petersen T, Dording C, Neault N, Kornbluh R, Alpert J E, Nierenberg A A, Rosenbaum J F, Fava M (2002) A survey of prescribing practices in the treatment of depression. Prog Neuropsychopharmacol Biol Psychiatry 26: 177-187
17. Quitkin F M, McGrath P J, Stewart J W, Deliyannides D, Taylor B P, Davies C A, Klein DF (2005) Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients. J Clin Psychiatry 66: 670-676
18. Quitkin F M, Petkova E, McGrath P J, Taylor B, Beasley C, Stewart J, Amsterdam J, Fava M, Rosenbaum J, Reimherr F, Fawcett J, Chen Y, Klein D (2003) When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry 160: 734-740
19. Ramana R, Paykel E S, Cooper Z, Hayhurst H, Saxty M, Surtees P G (1995) Remission and relapse in major depression: a two-year prospective follow-up study. Psychol Med 25: 1161-1170
20. Rush A J, Trivedi M H, Ibrahim H M, Carmody T J, Arnow B, Klein D N, Markowitz J C, Ninan P T, Kornstein S, Manber R, Thase M E, Kocsis J H, Keller M B (2003) The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), linician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54: 573-583
21. Rush A J, Zimmerman M, Wisniewski S R, Fava M, Hollon S D, Warden D, Biggs M M, Shores-Wilson K, Shelton R C, Luther J F, Thomas B, Trivedi M H (2005) Comorbid psychiatric disorders in depressed outpatients: Demographic and clinical features. J Affect Disord 87: 43-55
22. Rytsala H J, Melartin T K, Leskela U S, Sokero T P, Lestela-Mielonen P S, Isometsa E T (2005) Functional and work disability in major depressive disorder. J Nerv Ment Dis 193: 189-195
23. Shelton C I (2004) Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful? J. Clin Psychiatry 65 (Suppl 17): 29-33
24. Zimmerman M, Chelminski I, Posternak M A (2005) Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry 162: 1370-1372
25. Zimmerman M, Posternak M A, Chelminski I (2004) Using a self-report depression scale to identify remission in depressed outpatients. Am J Psychiatry 161: 1911-1913